Interviews

Keeping up with fast-paced clinical, regulatory, and policy innovation in healthcare is difficult. Our video interviews provide insight from key experts in the field of biosimilars, and help keep you informed.
Vivian Bykerk, MD, associate attending rheumatologist at the Hospital for Special Surgery, associate professor of medicine at Weill Cornell Medical College, describes her level of comfort with using biosimilars in practice. 
Vivian Bykerk, MD, associate attending rheumatologist at the Hospital for Special Surgery, associate professor of medicine at Weill Cornell Medical College, explains why treating rheumatoid arthritis (RA) early is crucial. 
Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses the burden of high-cost biologics.
Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses the challenge of prior authorizations.
Vivian Bykerk, MD, associate attending rheumatologist at the Hospital for Special Surgery, associate professor of medicine at Weill Cornell Medical College, discusses how cost affects patient access to biologic therapies.
Vivian Bykerk, MD, associate attending rheumatologist at the Hospital for Special Surgery, associate professor of medicine at Weill Cornell Medical College, provides an overview of what patients should know about biologic therapies versus conventional disease-modifying anti-rheumatic drugs.
Mark Cziraky, PharmD, CLS, describes what he sees as the future of the biosimilars space.
Cate Lockhart, PharmD, PhD, describes how the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was formed.
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses how his organization has helped bring down drug costs.
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses the role of patent opposition in giving patients access to high-cost drugs. 

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities


Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2018 Intellisphere, LLC. All Rights Reserved.